Giorgia Migliardi

发表

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

A. Bardelli, G. Migliardi, M. Risio, 2010, BMC Cancer.

Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas

G. Migliardi, L. Gammaitoni, M. Aglietta, 2012, Molecular Cancer Therapeutics.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

A. Sapino, G. Migliardi, F. Montemurro, 2011, Breast Cancer Research and Treatment.

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

G. Migliardi, F. Montemurro, M. Aglietta, 2011, BMC Cancer.

HER2 activating mutations are targets for colorectal cancer treatment.

Ron Bose, Wei Shen, Naveen Jain, 2015, Cancer discovery.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Davide Corà, Claudio Isella, Enzo Medico, 2011, Cancer discovery.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Andrea Bertotti, Simona Corso, Maria Apicella, 2013, Cancer discovery.

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Emanuel J. V. Gonçalves, F. Iorio, J. Sáez-Rodríguez, 2019, Nature.

Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient

A. Bardelli, C. Petti, A. Mellano, 2023, Frontiers in Oncology.

Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer

F. Nicolantonio, A. Bardelli, A. Sapino, 2017, Journal of the National Cancer Institute.

NEDD 8 pathway inhibition is effective in preclinical models of poorly differentiated , clinically aggressive colorectal cancer

F. Nicolantonio, A. Bardelli, A. Sapino, 2016 .

The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer

R. Scharpf, V. Velculescu, Siân Jones, 2015, Nature.

Efficient Transcriptional Targeting of Human Hematopoietic Stem Cells and Blood Cell Lineages by Lentiviral Vectors Containing the Regulatory Element of the Wiskott‐Aldrich Syndrome Gene

G. Migliardi, G. Morrone, W. Piacibello, 2009, Stem cells.

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Sabine Tejpar, Eva Budinská, Claudio Isella, 2015, Science Translational Medicine.

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

A. Bardelli, A. Muratore, L. Trusolino, 2012, Clinical Cancer Research.

The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling.

S. Bicciato, G. Migliardi, M. R. Ricciardi, 2015, Experimental hematology.

Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice.

F. Di Virgilio, D. Ferrari, R. Zini, 2012, Blood.

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer

L. Trusolino, A. Bertotti, G. Migliardi, 2013, Oncogene.

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer

D. Lambrechts, J. Tabernero, R. Dienstmann, 2021, Clinical Cancer Research.

HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor

D. Musiani, G. Migliardi, M. Gai, 2014, International journal of cancer.

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

L. Trusolino, A. Bertotti, G. Migliardi, 2023, Science Translational Medicine.

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype

I. Spiteri, P. Nuciforo, T. Graham, 2020, Science Translational Medicine.

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

F. Ciardiello, L. Trusolino, A. Bertotti, 2019, Journal of Experimental & Clinical Cancer Research.

Inhibition of erythropoiesis in malaria anemia: role of hemozoin and hemozoin-generated 4-hydroxynonenal.

G. Migliardi, O. Skorokhod, Luisa Caione, 2010, Blood.

Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab

G. Migliardi, M. Risio, W. Piacibello, 2008, Anti-cancer drugs.

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas

V. Torri, L. Trusolino, A. Bertotti, 2015, Clinical Cancer Research.

Sustained Inhibition of HER 3 and EGFR Is Necessary to Induce Regression of HER 2-Ampli fi ed Gastrointestinal Carcinomas

V. Torri, L. Trusolino, A. Bertotti, 2015 .

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

G. Camussi, G. Migliardi, S. Ferrari, 2009, Molecular Cancer.

Abstract C213: Sorafenib blocks tumor growth, angiogenesis, and metastatic potential in preclinical models of osteosarcoma through the inhibition of ERK1/2, MCL‐1, and ezrin pathways

G. Camussi, S. Ferrari, P. Picci, 2009 .

C-met inhibition blocks bone metastasis development induced by renal cancer stem cells

L. Trusolino, G. Migliardi, P. Comoglio, 2016, Oncotarget.

Cancer Therapy : Preclinical InhibitionofMEKandPI 3 K / mTORSuppressesTumorGrowth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

A. Muratore, L. Trusolino, A. Bertotti, 2012 .

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity

L. Trusolino, A. Bertotti, G. Migliardi, 2016, Journal of Translational Medicine.

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

F. Montemurro, M. Aglietta, M. Mello-Grand, 2011, BMC Cancer.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

V. Velculescu, L. Diaz, D. Zecchin, 2013, Cancer discovery.

HER2 activating mutations are targets for colorectal cancer treatment.

Adam C. Searleman, R. Bose, L. Trusolino, 2015, Cancer discovery.

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Emanuel J. V. Gonçalves, F. Iorio, J. Sáez-Rodríguez, 2019, Nature.

Abstract 659: Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas

L. Trusolino, A. Bertotti, F. Sassi, 2015 .

HSP 27 is required for invasion and metastasis triggered by hepatocyte growth factor

D. Musiani, G. Migliardi, M. Gai, 2013 .